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We examined data from the ARTEMIS DISK Antifungal Surveillance Program to describe geographic and
temporal trends in the isolation of Candida parapsilosis from clinical specimens and the in vitro susceptibilities
of 9,371 isolates to fluconazole and voriconazole. We also report the in vitro susceptibility of bloodstream
infection (BSI) isolates of C. parapsilosis to the echinocandins, anidulafungin, caspofungin, and micafungin. C.
parapsilosis represented 6.6% of the 141,383 isolates of Candida collected from 2001 to 2005 and was most
common among isolates from North America (14.3%) and Latin America (9.9%). High levels of susceptibility
to both fluconazole (90.8 to 95.8%) and voriconazole (95.3 to 98.1%) were observed in all geographic regions
with the exception of the Africa and Middle East region (79.3 and 85.8% susceptible to fluconazole and
voriconazole, respectively). C. parapsilosis was most often isolated from blood and skin and/or soft tissue
specimens and from patients hospitalized in the medical, surgical, intensive care unit (ICU) and dermatology
services. Notably, isolates from the surgical ICU were the least susceptible to fluconazole (86.3%). There was
no evidence of increasing azole resistance over time among C. parapsilosis isolates tested from 2001 to 2005. Of
BSI isolates tested against the three echinocandins, 92, 99, and 100% were inhibited by concentrations of <2
g/ml of anidulafungin (621 isolates tested), caspofungin (1,447 isolates tested), and micafungin (539 isolates
tested), respectively. C. parapsilosis is a ubiquitous pathogen that remains susceptible to the azoles and
echinocandins; however, both the frequency of isolation and the resistance of C. parapsilosis to fluconazole and
voriconazole may vary by geographic region and clinical service.
Candida parapsilosis is the most common non-albicans spe-
cies of Candida isolated from blood cultures in most regions of
the world outside of the United States (2, 3, 8, 12, 24, 37, 44,
45, 50). C. parapsilosis is an exogenous pathogen that may be
found on skin rather than mucosal surfaces (3, 5, 10, 18, 36, 56,
58). C. parapsilosis is known for the ability to form biofilms on
catheters and other implanted devices (6, 10, 13, 17, 18, 20, 53),
for nosocomial spread by hand carriage, and for persistence in
the hospital environment (3, 8, 10, 14, 18, 20, 35, 48, 50, 51, 58).
It is also well known for causing infections in infants and
neonates (10, 15, 18, 21, 22, 45, 49, 51, 52, 59).
The frequency of invasive candidiasis due to C. parapsilosis
has increased in recent years (44, 45), most notably in Spain (3)
and in Latin America (8, 11, 20, 24, 37, 50). Fortunately,
bloodstream infection (BSI) due to this species is associated
with a significantly lower mortality rate than are infections due
to other common species of Candida (1, 2, 16, 29, 31, 48).
Although C. parapsilosis is not considered prone to devel-
oping antifungal resistance (2, 8, 12, 14, 16, 29, 37, 44, 45, 48,
54, 55), several recent reports suggest that decreased suscep-
tibility of C. parapsilosis to azoles and echinocandins may be
cause for concern (3, 5, 8–10, 25, 26, 29, 46, 51, 54, 55, 57). As
early as 1994, Nguyen et al. (29) noted that C. parapsilosis was
the most common non-albicans species of Candida recovered
in fluconazole-breakthrough fungemia in a prospective multi-
center observational study of candidemia. Two recent out-
breaks of C. parapsilosis BSI, one in an adult intensive care unit
(ICU) (10) and one in a neonatal ICU (NICU) (51), serve to
emphasize the importance of the confluence of patient, organ-
ism, and environmental or behavioral factors in perpetuating
the spread of this exogenous pathogen. In both instances, ex-
tensive use of fluconazole, suboptimal hand hygiene and cath-
eter care, and a seriously ill patient population conspired to
generate an epidemic strain of C. parapsilosis with decreased
susceptibility to fluconazole that was transmitted throughout
the respective ICU environments. It was postulated that the
decreased susceptibility of the epidemic strains to fluconazole
provided a selective advantage, allowing C. parapsilosis coloni-
zation of skin and catheter surfaces with subsequent transmis-
sion facilitated by poor handwashing practices (10, 51).
The fact that C. parapsilosis is intrinsically less susceptible to
the echinocandin class of antifungal agents relative to that of
C. albicans or C. glabrata is well known (30, 38–41, 45, 47) and
* Corresponding author. Mailing address: Medical Microbiology Di-
vision, C606 GH, Department of Pathology, University of Iowa Col-
lege of Medicine, Iowa City, IA 52242. Phone: (319) 356-8615. Fax:
(319) 356-4916. E-mail: michael-pfaller@uiowa.edu.
 Published ahead of print on 16 January 2008.
842
is supported by the documentation of Fks1 polymorphisms that
are characteristic of the species and confer reduced suscepti-
bility to all three echinocandins (anidulafungin, caspofungin,
and micafungin) (33, 34). Furthermore, caspofungin has been
shown to exhibit markedly delayed killing kinetics against C.
parapsilosis compared to C. albicans (4). Although in their
phase III clinical trials both caspofungin (25) and micafungin
(19) were found to be as effective against C. parapsilosis as
amphotericin B deoxychocolate and liposomal amphotericin B,
respectively, it is notable that in the subgroup of patients with
C. parapsilosis infection, 5 of 20 patients had persistently pos-
itive cultures at the end of caspofungin therapy compared to
none in the amphotericin B group. Likewise, Reboli et al.
reported that anidulafungin had a lower rate than fluconazole
(69% versus 88%, respectively) at mediating microbiological
eradication of C. parapsilosis invasive infection (46).
Perhaps the most alarming evidence regarding the emer-
gence of echinocandin resistance in C. parapsilosis is that re-
ported by Moudgal et al. (26) and Vazquez et al. (57) from
Detroit, MI. In a case report of C. parapsilosis prosthetic valve
endocarditis, Moudgal et al. (26) described the emergence of
resistance to fluconazole, voriconazole, caspofungin, and mi-
cafungin (but not anidulafungin) after initial therapy with flu-
conazole and caspofungin. Subsequently, Vazquez et al. (57)
documented an increase in the recovery of multi-echinocandin,
multi-azole-resistant C. parapsilosis from patients in the burn
unit of their hospital. The development, and subsequent nos-
ocomial expansion, of echinocandin- and azole-resistant C.
parapsilosis has important clinical implications. Continued
monitoring for the emergence of this multidrug-resistant phe-
notype of C. parapsilosis is clearly warranted.
Despite the importance of C. parapsilosis as a nosocomial
fungal pathogen, few studies have addressed the global epide-
miology and antifungal susceptibility profile of C. parapsilosis
(3, 58). Most of the available information regarding C. parap-
silosis comes from single institutions (5, 10, 24, 26, 48, 50, 51)
or represents a limited geographical region (3, 8, 29) and does
not address frequency of isolation or resistance over time and
among various clinical services or specimen types. Given the
potential for decreased susceptibility of C. parapsilosis to
azoles and echinocandins, it seems prudent to gather addi-
tional information regarding this opportunistic fungal patho-
gen. In the present study, we use the extensive database pro-
vided by the ARTEMIS DISK Antifungal Surveillance
Program (44) to describe geographical and temporal trends in
the isolation of C. parapsilosis from clinical specimens col-
lected in 124 medical centers worldwide between 2001 and
2005, the types of specimens and clinical services in which C.
parapsilosis infections are recognized, and the in vitro suscep-
tibilities of 9,371 clinical isolates, including 2,834 BSI isolates
of this species, to fluconazole and voriconazole, as determined
by standardized disk diffusion testing. The in vitro susceptibil-
ity of BSI isolates to caspofungin, anidulafungin, and micafun-
gin was also determined by using Clinical and Laboratory Stan-
dards Institute (CLSI) broth microdilution (BMD) methods.
MATERIALS AND METHODS
Organisms and test sites. A total of 141,383 isolates of Candida spp., including
9,371 isolates of C. parapsilosis, from 124 different medical centers in various
regions—Asia-Pacific (23 sites), Latin America (16 sites), Europe (64 sites),
Africa and the Middle East (11 sites), and North America (10 sites)—were
collected and tested against fluconazole and voriconazole between January 2001
and December 2005. All Candida spp. considered pathogens from all body sites
(e.g., blood, normally sterile body fluids [NSBF], deep tissue biopsy, genital tract,
urine, respiratory tract, skin, and soft tissue) and isolates from all in-hospital and
outpatient locations during the study period from 2001 thru 2005 were tested. Of
the 2,834 BSI isolates of C. parapsilosis collected, 1,447 were sent to the Uni-
versity of Iowa (Iowa City) for testing against caspofungin; 621 of these isolates
were also tested against anidulafungin, and 539 were tested against micafungin
based on the availability of the antifungal agents from their respective manufac-
turers.
Data for C. parapsilosis were stratified by year of isolation, geographic region,
clinical service (hospital location), and specimen type. Candida spp. considered
by the local site investigator to be colonizers, i.e., not associated with pathology,
were excluded, as were duplicate isolates (the same species and the same sus-
ceptible-resistant biotype profile within any 7-day period). Identification of iso-
lates was performed in accordance with each site’s routine methods (44).
Susceptibility test methods. Disk diffusion testing of fluconazole and voricon-
azole was performed as described previously (44) and in accordance with CLSI
document M44-A (28). Agar plates (90, 100, or 150 mm in diameter) containing
Mueller-Hinton agar (obtained locally at all sites) supplemented with 2% glucose
and 0.5 g of methylene blue per ml at a depth of 4.0 mm were used. The agar
surface was inoculated by using a swab dipped in a cell suspension adjusted to the
turbidity of a 0.5 McFarland standard. Fluconazole (25 g) and voriconazole (1
g) disks (Becton Dickinson, Sparks, MD) were placed onto the surfaces of the
inoculated plates, and the plates were incubated in air at 35 to 37°C and read at
18 to 24 h. Zone diameter endpoints were read at 80% growth inhibition by using
a BIOMIC image analysis plate reader system (Giles Scientific, Santa Barbara,
CA) (44).
The MICs of anidulafungin, caspofungin, and micafungin were determined by
BMD as described previously (39–41). All isolates were tested in RPMI broth
with 24 h of incubation and a prominent reduction in growth (50%) relative to
control (MIC-2) endpoint criteria.
The interpretive criteria for fluconazole and voriconazole disk diffusion tests
were those of the CLSI (28, 42, 43) and are as follows: susceptible (S), zone
diameters of 19 mm (fluconazole) and 17 mm (voriconazole); susceptible
dose dependent (SDD), zone diameters of 15 to 18 mm (fluconazole) and 14 to
16 mm (voriconazole); and resistant (R), zone diameters of 14 mm (flucon-
azole) and13 mm (voriconazole). The corresponding MIC breakpoints (27, 42,
43) are as follows: S, MICs of 8 g/ml (fluconazole) and 1 g/ml (voricon-
azole); SDD, MICs of 16 to 32 g/ml (fluconazole) and 2 g/ml (voriconazole);
and R, MICs of 64 g/ml (fluconazole) and 4 g/ml (voriconazole).
The interpretive criteria for all three echinocandins were those recently as-
signed by the CLSI (June 2007): S, 2 g/ml; a category of R has not been
established for the echinocandins due to the paucity of “resistant” isolates
treated with an echinocandin. Isolates for which the echinocandin MIC is 2
g/ml are designated “nonsusceptible” (NS).
QC. Quality control (QC) was performed in accordance with CLSI documents
M44-A (fluconazole and voriconazole) and M27-A2 (all other agents) by using C.
albicans ATCC 90029, C. parapsilosis ATCC 22019, and C. krusei ATCC 6258
(27, 28). More than 99% of the QC results were within the acceptable limits (44).
Analysis of results. All disk zone diameters were read by electronic image
analysis and interpreted and recorded with the BIOMIC plate reader system
(Giles). Test results were sent by e-mail to Giles Scientific for analysis. The zone
diameter, susceptibility category (S, SDD, or R), and QC results were all re-
corded electronically. Patient and doctor names, duplicate test results (same
patient, same species, and same biotype results), and uncontrolled results were
automatically eliminated by the BIOMIC system prior to analysis. In the present
study, the fluconazole and voriconazole S, SDD, and R results for C. parapsilosis
were stratified by year of collection, geographic region, clinical specimen type,
and hospital location.
RESULTS
Isolation rates of C. parapsilosis over time and by geographic
region. A total of 141,383 isolates of Candida spp. were iso-
lated and identified at 124 study sites between January 2001
and December 2005 (44). C. parapsilosis ranked fourth among
22 different species of Candida, accounting for 6.6% of all
isolates (Table 1). Although the overall frequency of C. parap-
silosis increased from 4.8% in the years 1997 to 2000 to 6.6.%
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in the years 2001 to 2005 (44), the annual isolation rates were
relatively stable during the latter time period ranging from
6.9% in 2001 to 7.3% in 2003 and 5.6% in 2005.
C. parapsilosis was most frequently isolated in North Amer-
ica (14.3% of all Candida isolates) and Latin America (9.9%),
although the frequency of isolation varied considerably within
each of the five geographic locations, ranging from 0% (Indo-
nesia) to 16.9% (Australia) in the Asia-Pacific region, from
1.3% (Slovakia) to 7.8% (Spain and Turkey) in Europe, and
from 1.2% (Ecuador) to 12.8% (Brazil) in Latin America (Ta-
bles 1 and 2).
Geographic variation in susceptibility of C. parapsilosis to
fluconazole and voriconazole. Table 2 represents the in vitro
susceptibilities of C. parapsilosis to fluconazole and voricon-
azole stratified by country and geographic region of origin, as
TABLE 1. Variation in frequency of C. parapsilosis by
geographic regiona
Region Total no. of Candidaspecies isolates
Total no. (%) of
C. parapsilosis isolates
Asia-Pacific 27,845 2,263 (8.1)
Africa and Middle East 6,523 348 (5.3)
Europe 77,268 3,388 (4.4)
Latin America 19,895 1,960 (9.9)
North America 9,852 1,412 (14.3)
Total 141,383 9,371 (6.6)
a Data were obtained from the ARTEMIS DISK Global Antifungal Surveil-
lance Program (2001 to 2005). Isolates represent all incident isolates from all
sites of infection.
TABLE 2. Geographic variation in susceptibility of C. parapsilosis to fluconazole and voriconazole
Region or country
% by categorya
Fluconazole Voriconazole
N S SDD R N S SDD R
Asia-Pacific 2,263 90.8 4.6 4.6 2,092 95.3 2.6 2.1
Australia 124 99.2 0.8 124 99.2 0.8
China 121 87.6 4.1 8.3 121 92.6 3.3 4.1
India 32 90.6 6.3 3.1 31 100.0
Malaysia 1,521 89.2 5.5 5.3 1,353 94.6 3.4 2.0
South Korea 186 99.5 0.5 185 99.5 0.5
Taiwan 262 92.0 3.4 4.6 261 94.6 1.6 3.8
Thailand 17 88.2 11.8 17 100.0
Europe 3,388 95.8 1.8 2.4 3,298 98.1 0.8 1.1
Belgium 104 98.1 1.9 103 98.1 1.9
Czech Republic 300 99.0 1.0 283 100.0
France 94 84.0 8.6 7.4 77 96.1 2.6 1.3
Germany 135 99.3 0.7 135 99.3 0.7
Greece 36 83.3 5.6 11.1 36 94.4 2.8 2.8
Hungary 259 90.3 3.5 6.2 237 95.4 1.2 3.4
Italy 374 97.9 1.0 1.1 374 99.2 0.5 0.3
The Netherlands 151 95.4 2.6 2.0 151 96.7 1.3 2.0
Norway 7 100.0 7 100.0
Poland 68 91.2 1.4 7.4 68 95.6 1.5 2.9
Portugal 215 96.7 0.5 2.8 215 97.7 0.4 1.9
Russia 213 87.8 3.7 8.5 213 96.7 1.9 1.4
Slovakia 47 91.5 4.2 4.3 47 93.6 6.4
Spain 496 99.0 0.6 0.4 496 99.6 0.2 0.2
Switzerland 88 98.9 1.1 89 100.0
Turkey 109 96.3 1.9 1.8 93 98.9 1.1
United Kingdom 692 96.8 1.9 1.3 674 97.9 1.2 0.9
Latin America 1,960 93.7 4.0 2.3 1,910 97.8 1.2 1.0
Argentina 715 93.7 4.8 1.5 702 98.4 1.0 0.6
Brazil 500 97.2 1.2 1.6 496 97.8 1.0 1.2
Colombia 465 89.9 5.4 4.7 440 96.4 1.8 1.8
Ecuador 32 87.5 12.5 32 96.9 3.1
Mexico 98 95.9 3.1 1.0 88 98.9 1.1
Venezuela 150 93.3 4.0 2.7 152 98.7 0.6 0.7
Africa and Middle East 348 79.3 5.2 15.5 345 85.8 2.9 11.3
South Africa 256 74.2 5.5 20.3 253 81.0 4.0 15.0
Israel 54 94.4 3.7 1.9 54 100.0
Saudi Arabia 38 92.1 5.3 2.6 38 97.4 2.6
North America 1,412 94.3 1.8 3.9 1,396 97.1 0.9 2.0
Canada 69 97.1 1.5 1.4 69 100.0
United States 1,343 94.2 1.8 4.0 1,327 96.9 0.9 2.2
Total 9,371 93.3 3.0 3.6 9,041 96.8 1.4 1.9
a All isolates were tested by the disk diffusion method performed in accordance with CLSI standard M44-A. S, susceptible, with zone diameters of 19 mm for
fluconazole and 17 mm for voriconazole; SDD, susceptible dose dependent, with zone diameters of 15 to 18 mm for fluconazole and 14 to 16 mm for voriconazole;
R, resistant, with zone diameters of 14 mm for fluconazole and 13 mm for voriconazole.
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determined by CLSI disk diffusion testing. Overall, C. parap-
silosis exhibited slightly decreased susceptibility to fluconazole
(93.3% S, 3.6% R) compared to that of C. albicans (97.9% S,
1.5% R) (data not shown).
A surprising degree of variation in the susceptibility of C.
parapsilosis to fluconazole was observed across the first five
broad regions: isolates from Europe were the most susceptible
(95.8% S, 2.4% R), and the lowest overall susceptibility was
seen among isolates from the Africa and Middle East region
(79.3% S, 15.5% R), the latter being largely accounted for by
isolates from South Africa (74.2% S, 20.3% R). No other
country reported susceptibility rates of less than 80%; how-
ever, the susceptibility rates were less than 90% in eight coun-
tries: China (87.6%), Malaysia (89.2%), Thailand (88.2%),
France (84.0%), Greece (83.3%), Russia (87.8%), Colombia
(89.9%), and Ecuador (87.5%). More than 95% of isolates
were susceptible to fluconazole in 16 countries: Australia
(99.2%), South Korea (99.5%), Belgium (98.1%), the Czech
Republic (99.0%), Germany (99.3%), Italy (97.9%), The Neth-
erlands (95.4%), Norway (100%), Portugal (96.7%), Spain
(99.0%), Switzerland (98.9%), Turkey (96.3%), the United
Kingdom (96.8%), Brazil (97.2%), Mexico (95.9%), and Can-
ada (97.1%).
Voriconazole was always more active against C. parapsilosis
than fluconazole, irrespective of geographic region. In contrast
to fluconazole, only a slight variation in voriconazole activity
was observed across the different countries and regions, rang-
ing from a low of 81% susceptible in South Africa to a high of
100% in India, Thailand, Czech Republic, Norway, Switzer-
land, Israel, and Canada. More than 98% of isolates in 17 of
the 35 countries were susceptible to voriconazole.
Trends in resistance to fluconazole and voriconazole among
C. parapsilosis isolates over time. There was no evidence of
increasing resistance to the azoles among C. parapsilosis iso-
lates tested between 2001 and 2005. Resistance to fluconazole
ranged from 4.2% in 2001 to 3.1% in 2003 and was 4.2% in
2005. Resistance to voriconazole was 1.9% in 2001, peaked at
2.3% in 2002, and was 1.9% in 2005.
Variation in the frequency of isolation and antifungal sus-
ceptibility profile of C. parapsilosis by clinical service. The
clinical services reporting the isolation of C. parapsilosis from
patient specimens included the hematology-oncology service,
medical and surgical services, intensive care units (medical,
surgical, and neonatal), the dermatology service, the urology
service, and the outpatient service (Table 3). Those strains
from services with only a few isolates and those for which a
clinical service was not specified were included in the category
“other, not otherwise specified (NOS)”.
Candida parapsilosis was isolated most frequently from pa-
tients on the Dermatology service (20.9%) and least frequently
from patients on the Hematology-Oncology service (3.6%).
Only 6% of the Candida spp. isolated from ICU patients in the
present study were C. parapsilosis. However, C. parapsilosis was
isolated much more frequently from patients in the NICU
(15.4% of all Candida spp. from NICU).
There was little variation in susceptibility to either triazole
across the different services. More than 90% of isolates were
susceptible to both fluconazole and voriconazole irrespective
of the different clinical services.
Variation in the frequency of isolation and antifungal sus-
ceptibility profile of C. parapsilosis by clinical specimen type.
The major specimen types yielding C. parapsilosis as a putative
TABLE 3. Susceptibility of C. parapsilosis to fluconazole and voriconazole by clinical service
Clinical service (total no. of isolates)a Antifungal agent No. of isolatestested
% of isolates from
serviceb
% of isolatesc
S SDD R
Hematology-oncology (8,432) Fluconazole 305 3.6 94.8 2.6 2.6
Voriconazole 301 98.7 0.7 0.7
Medical (33,681) Fluconazole 2,144 6.4 93.7 2.6 3.7
Voriconazole 2,100 96.7 1.4 2.0
Surgical (8,869) Fluconazole 561 6.3 93.9 3.0 3.0
Voriconazole 547 96.9 1.3 1.8
ICU (18,691) Fluconazole 1,119 6.0 91.3 3.6 5.1
Voriconazole 1,083 95.3 1.4 3.3
Dermatology (2,519) Fluconazole 527 20.9 93.0 4.0 3.0
Voriconazole 502 97.2 1.2 1.6
Urology (1,293) Fluconazole 61 4.7 91.8 4.9 3.3
Voriconazole 60 96.7 3.3
Outpatient (11,621) Fluconazole 811 7.0 95.2 2.8 2.0
Voriconazole 797 98.4 0.8 0.9
Other, NOSd (38,649) Fluconazole 3,843 9.9 93.2 3.1 3.7
Voriconazole 3,653 96.5 1.6 1.9
a That is, the total number of Candida isolates from each service.
b C. parapsilosis as a percentage of all isolates from that clinical service.
c S, SDD, and R are as defined in Table 2, footnote a.
d Other, NOS, other, not otherwise specified.
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pathogen included blood, NSBF, urine, respiratory, skin and
soft tissue, and genital specimens (Table 4). The isolates from
uncommon specimen types and those for which a specimen
type was not recorded were grouped under the category
“Misc., NOS” (miscellaneous, not otherwise specified).
C. parapsilosis was isolated most frequently from blood and
skin and soft tissue specimens and was isolated infrequently
from urine, respiratory, and genital tract specimens. Both flu-
conazole and voriconazole were quite active (90% S) against
isolates of C. parapsilosis irrespective of specimen type.
Activity of echinocandin antifungal agents against blood-
stream isolates of C. parapsilosis. Previously, we and others
have shown that echinocandin MICs are consistently higher for
C. parapsilosis than for C. albicans when tested by BMD meth-
ods (30, 39–41). When tested against anidulafungin, caspofun-
gin, and micafungin using the CLSI BMD method, 93.2, 99.6,
and 100% of the BSI isolates of C. parapsilosis were susceptible
to the three echinocandins, respectively, at the recently as-
signed (June 2007) CLSI breakpoint concentration of 2
g/ml (Table 5). The differences in potency among the three
agents are best reflected by the modal MICs: caspofungin (0.25
to 0.5 g/ml), micafungin (1.0 g/ml), and anidulafungin (2.0
g/ml). This pattern was unchanged across the different geo-
graphic regions (data not shown). Importantly, we did not
observe a multi-echinocandin, multi-azole-resistant phenotype
such as that reported by Moudgal et al. (26) and Vazquez et al.
(57). Among nine isolates that were found to be resistant to
fluconazole (MIC, 64 g/ml), all were susceptible (MIC, 2
g/ml) to anidulafungin (range, 1 to 2 g/ml), caspofungin
(range, 0.25 to 2 g/ml), and micafungin (range, 1 to 2 g/ml).
Likewise, the Detroit phenotype for echinocandin resistance
(i.e., caspofungin- and micafungin-resistant, anidulafungin-sus-
ceptible) was not detected among 539 isolates tested against all
three echinocandins.
DISCUSSION
The results of this extensive survey of C. parapsilosis both
confirm and extend previous observations regarding this spe-
cies (1, 3, 8, 15, 29, 48, 50, 58). We have demonstrated that the
frequency of isolation of C. parapsilosis varies considerably
among countries, clinical services, and specimen types and
confirm the increased frequency in Latin America, neonatal
ICUs, and blood and dermatologic specimens. Likewise, we
confirm the general susceptibility of C. parapsilosis to both
fluconazole and voriconazole and yet document an unusual
pocket of azole resistance in South Africa.
Although fluconazole is well known to have good activity
TABLE 4. Susceptibility of C. parapsilosis to fluconazole and voriconazole by specimen type
Specimen type/site
(total no. of isolates)a Antifungal agent
No. of isolates
tested
% of isolates
from siteb
% of isolatesc
S SDD R
Blood (14,887) Fluconazole 2,834 19.0 93.1 2.7 4.2
Voriconazole 2,755 96.8 1.0 2.2
NSBF (6,055) Fluconazole 373 6.2 94.1 2.7 3.2
Voriconazole 368 97.3 0.5 2.2
Urine (18,168) Fluconazole 806 4.4 91.1 4.5 4.5
Voriconazole 771 96.1 1.8 2.1
Respiratory (39,523) Fluconazole 1,008 2.6 94.2 3.4 2.4
Voriconazole 979 97.3 1.2 1.5
Skin or soft tissue (8,290) Fluconazole 1,220 14.7 95.1 3.0 1.9
Voriconazole 1,196 97.9 1.2 0.9
Genital (31,157) Fluconazole 1,009 3.2 95.7 2.3 2.0
Voriconazole 926 97.3 1.3 1.4
Misc. NOS (23,303) Fluconazole 2,121 9.1 91.7 3.3 5.0
Voriconazole 2,046 95.7 2.0 2.3
a That is, the total number of Candida isolates from each specimen type. Misc. NOS, miscellaneous, not otherwise specified.
b C. parapsilosis as a percentage of all isolates from that specimen type.
c S, SDD, and R are as defined in Table 2, footnote a.
TABLE 5. In vitro activity of anidulafungin, caspofungin, and micafungin against bloodstream isolates of C. parapsilosisa
Antifungal agent No. tested
Cumulative % of isolates at an MIC (g/ml) of:
0.015 0.03 0.06 0.12 0.25 0.5 1 2 4
Anidulafungin 621 0.3 0.8 0.8 0.8 1.9 4.7 29.3 93.2 100
Caspofungin 1,447 0.3 0.9 3.7 12.4 49.9 89.4 98.8 99.6 100
Micafungin 539 0.2 0.2 0.2 0.6 5.2 22.5 75.3 100
a Isolates were tested in RPMI 1640 broth with 24 h of incubation and a prominent reduction endpoint criterion (MIC-2).
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against C. parapsilosis, it is clear from this survey that de-
creased susceptibility may occur in certain geographic regions
and in select institutions (10, 26, 51, 57), suggesting that mon-
itoring of local susceptibility profiles may be useful. Decreased
susceptibility to fluconazole among C. parapsilosis may be en-
hanced by the proclivity of this species to form extensive bio-
films on catheters and other devices (13, 17, 18, 20). Because
the source of C. parapsilosis fungemia is a vascular catheter in
more than 50% of cases and such infections occur commonly in
patients who had received prior antifungal treatment (3), an
adequate response to fluconazole alone may not be achieved,
and administration of this agent should be coupled with
prompt removal of the catheter to ensure an optimal response
(32). Furthermore, despite excellent overall activity of voricon-
azole against C. parapsilosis, it must be recognized that only
36.7% of fluconazole-resistant isolates of C. parapsilosis retain
susceptibility to voriconazole (44).
Given that C. parapsilosis is well known as a superficial
colonizer of cutaneous surfaces and as a cause of onychomy-
cosis (5, 7, 23, 56), it is not surprising that we found it to be
isolated commonly from skin and soft tissue infections in pa-
tients on the Dermatology service. Bonassoli et al. (5) found a
high frequency of C. parapsilosis colonization of the hands of
healthy volunteers and health care workers and noted that
these colonizing strains exhibited the same potential virulence
characteristics as those isolated from sites of infection. Thus,
hand colonization with virulent strains of C. parapsilosis cou-
pled with poor hand washing and catheter care may serve as a
nosocomial threat to seriously ill patients (10, 18).
Although C. parapsilosis is often reported to cause infections
among patients hospitalized in the ICU (1, 3, 10, 51), only 6%
of the Candida spp. isolated from ICU patients in the present
study were C. parapsilosis. However, C. parapsilosis was iso-
lated much more frequently from patients in the NICU (15.4%
of all Candida spp.) than from those in the medical (5.8%) or
surgical (3.4%) ICU. This finding supports previous observa-
tions regarding candidiasis in the NICU (15, 21, 22, 49, 51, 52,
58, 59).
Although the role of C. parapsilosis as a pathogen when
isolated from nonsterile sites such as the respiratory, urinary,
and genital tracts is debated, isolation from blood and NSBF
must be considered significant. Thus, it is worth noting that the
single most common specimen to yield C. parapsilosis in cul-
ture was blood (Table 4). Prior colonization of mucosal sites is
rare among patients with C. parapsilosis fungemia, further con-
firming the exogenous nature of this pathogen (3).
Perhaps the most encouraging information from this survey
is the lack of any multi-azole, multi-echinocandin-resistant
strains of C. parapsilosis. Although this species is innately less
susceptible to the echinocandins than many other species of
Candida, the vast majority of isolates remain susceptible to all
three echinocandins (Table 5). Specifically, the epidemic phe-
notype reported from Detroit, MI (57), was not detected. Po-
tency differences among the three echinocandins were detect-
ed; however, previous studies have found that such differences
in vitro were normalized by the addition of serum to the test
medium and did not prove to be important in vivo (34). Nev-
ertheless, the experience in Detroit (26, 57) and the less-than-
stellar results against C. parapsilosis in clinical trials (25, 46, 54)
suggest that this species should be carefully monitored with
respect to emerging echinocandin resistance.
In summary, we have used the extensive and validated da-
tabase of the ARTEMIS DISK Antifungal Surveillance Pro-
gram (44) to increase our understanding of C. parapsilosis as an
opportunistic pathogen. Our findings confirm that this species
is an emerging pathogen in Latin America and is also impor-
tant in North America. This species may exhibit decreased
susceptibility to fluconazole in some geographic locations and
is generally susceptible to voriconazole and the echinocandins.
It is most likely to be isolated from blood and is often associ-
ated with intravascular catheters and parenteral nutrition. The
detection of BSIs with C. parapsilosis should raise a “red flag”
regarding breaks in catheter care and infection control proce-
dures, since it usually signifies the exogenous introduction of
the offending pathogen into an already compromised host (3,
10, 44, 58).
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